A Phase 3 interventional study of insulin degludec/liraglutide and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 76 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 49 in phase 3, and was the 45th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 819 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 48th largest by enrollment of the 428 interventional ones that give a count, is one of 17 that started in 2015, is one of 187 in phase 3, and was the 405th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 819 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: insulin degludec
Drug: liraglutide
Drug pages: Insulin degludec · Liraglutide
Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analyses were performed to test the hypotheses: non-inferiority of IDegLira vs. IDeg and superiority of IDegLira vs. Liraglutide (Lira).
Time frame: Week 0, Week 52
Change From Baseline in Body Weight (kg)
Change from baseline (week 0) in body weight after 52 weeks of treatment.
Time frame: Week 0, Week 52
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: Weeks 0-52
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analysis was performed to test the hypothesis: superiority of IDegLira vs. IDeg.
Time frame: Week 0, Week 52
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG after 52 weeks
Time frame: Week 0, Week 52
Insulin Dose
Actual daily total insulin dose after 52 weeks of treatment.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 7.0%
Number of subjects with HbA1c less than 7.0% after 52 weeks of treatment.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero
Number of subjects with HbA1c less than 7.0% and without weight gain after 52 weeks of treatment.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
Number of subjects with HbA1c less than 7.0% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than 7.0% and without weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 6.5%
Number of subjects with HbA1c less than 6.5% after 52 weeks of treatment.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero
Number of subjects with HbA1c less than 6.5% and without weight gain after 52 weeks of treatment.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 6.5% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
Number of subjects with HbA1c less than 6.5% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 52 weeks of treatment
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than 6.5% with no weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 52 weeks of treatment
Change in Waist Circumference
Change from baseline (week 0) in waist circumference after 52 weeks of treatment.
Time frame: Week 0, Week 52
Change in Blood Pressure (Systolic and Diastolic)
Change from baseline in blood pressure (systolic and diastolic) after 52 weeks of treatment.
Time frame: Week 0, Week 52
Self-Measured Blood Glucose (SMBG) 9-point Profile: 9-point Profile (Individual Points in the Profile)
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.
Time frame: After 52 weeks of the treatment
Change in SMBG 9-point Profile - Mean of the 9-point Profile
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.
Time frame: Week 0, week 52
Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.
Time frame: Week 0, week 52
Total Cholesterol as a Ratio to Baseline at 52 Weeks
Total cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Low density lipoprotein (LDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks
High density lipoprotein (HDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Very low density lipoprotein (VLDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Triglycerides as a Ratio to Baseline at 52 Weeks
Triglycerides after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Free Fatty Acids as a Ratio to Baseline at 52 Weeks
Free fatty acids after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Fasting C-peptide as a Ratio to Baseline at 52 Weeks
Fasting C-peptide after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Fasting Human Insulin as a Ratio to Baseline at 52 Weeks
Fasting human insulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Fasting Glucagon as a Ratio to Baseline at 52 Weeks
Fasting glucagon after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Proinsulin as a Ratio to Baseline at 52 Weeks
Proinsulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time frame: After 52 weeks of treatment
Number of Treatment Emergent Adverse Events (TEAEs)
Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Time frame: 0-52 weeks
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: 0-52 weeks
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: 0-52 weeks
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition
Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.
Time frame: 0-52 weeks
Anti-drug Antibodies: Anti-insulin Degludec Antibodies
Insulin degludec (IDeg)-specific antibodies were measured at week 52, as %B/T (percentage of bound \& precipitated radioactive drug/total added drug to the sample). A sample is measured in 2 different series. In series 1, the radioactive IDeg (tracer) and surplus unlabeled IDeg are added to the sample. In series 2, the tracer and surplus unlabeled human insulin are added to the sample. Series 1 represents unspecific background binding. Series 2 represents IDeg specific antibodies including unspecific background binding. The reported %B/T is calculated by subtracting the background %B/T in series 1 from the %B/T result in series 2. If the background result has higher values than the %B/T in series 2, the resulting value is negative %B/T. Here, a negative %B/T value means that the test samples do not have IDeg-specific antibodies. The reason for getting a negative value for %B/T is due to variation in the analytical background. Thus, the results presented are not a change from baseline.
Time frame: at week 52
Anti-drug Antibodies: Number of Participants Positive or Negative for Anti-liraglutide Antibodies
Anti-liraglutide antibodies were measured at week 52. Number of participants positive or negative for anti-liraglutide antibodies at week 52 were reported.
Time frame: at week 52
Change in Clinical Evaluation: Fundoscopy or Fundus Photography
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 52.
Time frame: at screening (week -2 to week 0), at week 52
Change in Clinical Evaluation: Electrocardiogram (ECG)
The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 52.
Time frame: at screening (week -2 to week 0), at week 52
Change in Clinical Evaluation: Pulse
Change in pulse after 52 weeks of treatment.
Time frame: Week 0, week 52
Serum Concentrations of Insulin Degludec
Samples from the IDegLira and IDeg arms were analysed for serum concentrations of insulin degludec using validated ELISA assays.
Time frame: Weeks 2, 8, 16, 26, 44, 52
Plasma Concentrations of Liraglutide
Samples from the IDegLira and liraglutide arms were assayed for plasma concentrations of liraglutide using validated ELISA assays.
Time frame: Weeks 2, 8, 16, 26, 44, 52
The trial was conducted at 71 sites in Japan. 71 sites screened and randomised subjects.
| Milestone | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Started | 275 | 271 | 273 |
| Completed | 254 | 248 | 263 |
| Not completed | 21 | 23 | 10 |
| Withdrew: Adverse event | 8 | 6 | 6 |
| Withdrew: Unclassified | 1 | 4 | 0 |
| Withdrew: Withdrawal by subject | 8 | 10 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Protocol violation | 4 | 2 | 1 |
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analyses were performed to test the hypotheses: non-inferiority of IDegLira vs. IDeg and superiority of IDegLira vs. Liraglutide (Lira).
| Percentage of HbA1c | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira | -2.42 ± 1.04 | -1.80 ± 1.02 | -1.80 ± 0.92 |
Change from baseline (week 0) in body weight after 52 weeks of treatment.
| Kg | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change From Baseline in Body Weight (kg) | 2.9 ± 3.2 | 4.1 ± 4.3 | -1.0 ± 3.4 |
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes | 467 | 869 | 13 |
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analysis was performed to test the hypothesis: superiority of IDegLira vs. IDeg.
| Percentage of HbA1c | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg | -2.42 ± 1.04 | -1.80 ± 1.02 | -1.80 ± 0.92 |
Change from baseline (week 0) in FPG after 52 weeks
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -4.08 ± 2.47 | -3.97 ± 2.56 | -2.62 ± 1.95 |
Actual daily total insulin dose after 52 weeks of treatment.
| Insulin Units/Day | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Insulin Dose | 27.7 ± 14.8 | 34.8 ± 26.0 |
Number of subjects with HbA1c less than 7.0% after 52 weeks of treatment.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 245 | 189 | 208 |
| No | 30 | 82 | 65 |
Number of subjects with HbA1c less than 7.0% and without weight gain after 52 weeks of treatment.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 44 | 22 | 142 |
| No | 231 | 249 | 131 |
Number of subjects with HbA1c less than 7.0% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 227 | 169 | 206 |
| No | 43 | 96 | 65 |
Number of subjects with HbA1c less than 7.0% and without weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 37 | 22 | 141 |
| No | 233 | 243 | 130 |
Number of subjects with HbA1c less than 6.5% after 52 weeks of treatment.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 213 | 134 | 171 |
| No | 62 | 137 | 102 |
Number of subjects with HbA1c less than 6.5% and without weight gain after 52 weeks of treatment.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 41 | 17 | 126 |
| No | 234 | 254 | 147 |
Number of subjects with HbA1c less than 6.5% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 198 | 123 | 170 |
| No | 72 | 142 | 101 |
Number of subjects with HbA1c less than 6.5% with no weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 35 | 17 | 125 |
| No | 235 | 248 | 146 |
Change from baseline (week 0) in waist circumference after 52 weeks of treatment.
| Cm | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Waist Circumference | 2.5 ± 4.5 | 3.4 ± 5.2 | -1.1 ± 4.4 |
Change from baseline in blood pressure (systolic and diastolic) after 52 weeks of treatment.
| mmHg | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Systolic blood pressure | 1.7 ± 12.0 | 3.4 ± 14.3 | -1.8 ± 13.0 |
| Diastolic blood pressure | 0.5 ± 7.9 | 0.6 ± 9.3 | -0.4 ± 8.3 |
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Before breakfast | 5.90 ± 1.45 | 5.93 ± 1.64 | 7.35 ± 1.70 |
| 90 minutes after start of breakfast | 9.57 ± 2.83 | 10.43 ± 3.16 | 10.59 ± 3.25 |
| Before lunch | 6.01 ± 1.90 | 6.72 ± 2.59 | 6.87 ± 2.07 |
| 90 minutes after start of lunch | 9.85 ± 3.16 | 11.12 ± 3.04 | 10.59 ± 3.38 |
| Before dinner | 6.47 ± 2.44 | 6.90 ± 2.57 | 7.03 ± 2.04 |
| 90 minutes after start of dinner | 9.67 ± 3.01 | 10.89 ± 3.25 | 10.14 ± 3.03 |
| Bedtime | 8.27 ± 2.79 | 9.49 ± 3.28 | 8.73 ± 2.58 |
| At 4:00 a.m. | 6.12 ± 1.70 | 6.41 ± 2.18 | 7.27 ± 1.79 |
| Before breakfast the following day | 5.77 ± 1.56 | 5.71 ± 1.68 | 7.13 ± 1.68 |
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in SMBG 9-point Profile - Mean of the 9-point Profile | -4.60 ± 2.65 | -3.84 ± 2.63 | -3.46 ± 2.37 |
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner) | -0.74 ± 2.51 | -0.27 ± 2.39 | -1.01 ± 2.38 |
Total cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Total Cholesterol as a Ratio to Baseline at 52 Weeks | 0.92 ± 13.9 | 0.97 ± 11.9 | 0.94 ± 13.0 |
Low density lipoprotein (LDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks | 0.91 ± 23.4 | 0.99 ± 18.2 | 0.93 ± 24.2 |
High density lipoprotein (HDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks | 0.94 ± 16.4 | 0.94 ± 14.6 | 0.99 ± 14.5 |
Very low density lipoprotein (VLDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks | 0.92 ± 44.3 | 0.97 ± 42.1 | 0.91 ± 42.2 |
Triglycerides after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Triglycerides as a Ratio to Baseline at 52 Weeks | 0.91 ± 48.3 | 0.96 ± 44.2 | 0.91 ± 44.0 |
Free fatty acids after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Free Fatty Acids as a Ratio to Baseline at 52 Weeks | 0.74 ± 60.8 | 0.70 ± 59.3 | 0.93 ± 49.5 |
Fasting C-peptide after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Fasting C-peptide as a Ratio to Baseline at 52 Weeks | 0.61 ± 75.6 | 0.42 ± 82.6 | 1.12 ± 29.9 |
Fasting human insulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Fasting Human Insulin as a Ratio to Baseline at 52 Weeks | 0.90 ± 89.0 | 0.61 ± 81.1 | 1.52 ± 66.6 |
Fasting glucagon after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Fasting Glucagon as a Ratio to Baseline at 52 Weeks | 0.95 ± 27.9 | 0.94 ± 27.6 | 0.96 ± 25.7 |
Proinsulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Proinsulin as a Ratio to Baseline at 52 Weeks | 0.18 ± 231.5 | 0.17 ± 188.8 | 0.59 ± 85.9 |
Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
| Events | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 873 | 829 | 885 |
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes | 135 | 362 | 136 |
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 16 | 42 | 0 |
Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition | 4830 | 6340 | 162 |
Insulin degludec (IDeg)-specific antibodies were measured at week 52, as %B/T (percentage of bound \& precipitated radioactive drug/total added drug to the sample). A sample is measured in 2 different series. In series 1, the radioactive IDeg (tracer) and surplus unlabeled IDeg are added to the sample. In series 2, the tracer and surplus unlabeled human insulin are added to the sample. Series 1 represents unspecific background binding. Series 2 represents IDeg specific antibodies including unspecific background binding. The reported %B/T is calculated by subtracting the background %B/T in series 1 from the %B/T result in series 2. If the background result has higher values than the %B/T in series 2, the resulting value is negative %B/T. Here, a negative %B/T value means that the test samples do not have IDeg-specific antibodies. The reason for getting a negative value for %B/T is due to variation in the analytical background. Thus, the results presented are not a change from baseline.
| Percentage B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Anti-drug Antibodies: Anti-insulin Degludec Antibodies | 0.12 ± 3.34 | -0.11 ± 0.42 |
Anti-liraglutide antibodies were measured at week 52. Number of participants positive or negative for anti-liraglutide antibodies at week 52 were reported.
| Participants | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| Negative | 247 | 224 |
| Positive | 28 | 49 |
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 52.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Left eye - at screening visit - normal | 225 | 213 | 211 |
| Left eye - at screening visit - Abn, NCS | 10 | 16 | 14 |
| Left eye - at screening visit - Abn, CS | 39 | 42 | 47 |
| Left eye - week 52 - normal | 217 | 214 | 212 |
| Left eye - week 52 - Abn, NCS | 17 | 16 | 15 |
| Left eye - week 52 - Abn, CS | 40 | 41 | 45 |
| Right eye - at screening visit - normal | 224 | 212 | 207 |
| Right eye - at screening visit - Abn, NCS | 10 | 14 | 12 |
| Right eye - at screening visit - Abn, CS | 41 | 45 | 54 |
| Right eye - week 52 - normal | 220 | 217 | 209 |
| Right eye - week 52 - Abn, NCS | 14 | 14 | 15 |
| Right eye - week 52 - Abn, CS | 41 | 40 | 49 |
The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 52.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| At screening visit - normal | 228 | 230 | 222 |
| At screening visit - Abn, NCS | 40 | 38 | 41 |
| At screening visit - Abn, CS | 7 | 3 | 10 |
| Week 52 - normal | 238 | 232 | 233 |
| Week 52 - Abn, NCS | 30 | 35 | 34 |
| Week 52 - Abn, CS | 7 | 4 | 6 |
Change in pulse after 52 weeks of treatment.
| beats per minute | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Clinical Evaluation: Pulse | 3.9 ± 9.5 | 0.8 ± 8.9 | 4.2 ± 9.1 |
Samples from the IDegLira and IDeg arms were analysed for serum concentrations of insulin degludec using validated ELISA assays.
| pmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| At week 2 | 1468.7 ± 55.9 | 1477.1 ± 61.3 |
| At week 8 | 2246.0 ± 72.2 | 2524.6 ± 71.5 |
| At week 16 | 2511.0 ± 83.6 | 2856.4 ± 84.4 |
| At week 26 | 2597.3 ± 88.3 | 2946.9 ± 91.1 |
| At week 44 | 2766.6 ± 85.8 | 3238.8 ± 91.7 |
| At week 52 | 2393.8 ± 116.7 | 3124.4 ± 101.2 |
Samples from the IDegLira and liraglutide arms were assayed for plasma concentrations of liraglutide using validated ELISA assays.
| pmol/L | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| At week 2 | 5681.3 ± 49.4 | 6081.6 ± 65.4 |
| At week 8 | 9107.8 ± 61.4 | 14539.5 ± 71.0 |
| At week 16 | 10038.1 ± 69.5 | 14046.5 ± 73.0 |
| At week 26 | 9995.3 ± 77.5 | 13904.2 ± 91.8 |
| At week 44 | 8791.7 ± 81.0 | 12855.6 ± 112.7 |
| At week 52 | 7426.2 ± 103.5 | 12127.4 ± 142.4 |
Collected over Week 0 (randomisation) to week 52 (end of treatment) and 7 days after end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide | 1/275 (0.4%) | 17/275 (6.2%) | 153/275 (55.6%) |
| Insulin Degludec | 0/271 (0%) | 13/271 (4.8%) | 137/271 (50.6%) |
| Liraglutide | 0/273 (0%) | 14/273 (5.1%) | 158/273 (57.9%) |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Angina pectorisCardiac disorders | 2/275 | 0/271 | 0/273 |
| Acute myocardial infarctionCardiac disorders | 0/275 | 1/271 | 0/273 |
| Adrenal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/275 | 1/271 | 0/273 |
| Atrioventricular block completeCardiac disorders | 0/275 | 1/271 | 0/273 |
| Carpal tunnel syndromeNervous system disorders | 0/275 | 1/271 | 0/273 |
| Endometrial hyperplasiaReproductive system and breast disorders | 0/275 | 1/271 | 0/273 |
| Herpes zoster meningitisInfections and infestations | 0/275 | 1/271 | 0/273 |
| Hypoglycaemic unconsciousnessNervous system disorders | 0/275 | 1/271 | 0/273 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/275 | 1/271 | 0/273 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/275 | 1/271 | 0/273 |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 106/275 | 91/271 | 94/273 |
| ConstipationGastrointestinal disorders | 27/275 | 12/271 | 38/273 |
| DiarrhoeaGastrointestinal disorders | 15/275 | 12/271 | 24/273 |
| NauseaGastrointestinal disorders | 9/275 | 5/271 | 23/273 |
| Weight increasedInvestigations | 4/275 | 19/271 | 1/273 |
| Diabetic retinopathyEye disorders | 17/275 | 12/271 | 11/273 |
| EczemaSkin and subcutaneous tissue disorders | 16/275 | 6/271 | 9/273 |
| PharyngitisInfections and infestations | 11/275 | 15/271 | 9/273 |
| HeadacheNervous system disorders | 7/275 | 7/271 | 15/273 |
| Lipase increasedInvestigations | 6/275 | 0/271 | 15/273 |
| Age, Continuous(Years) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 56.9 ± 10.2 | 57.8 ± 9.9 | 56.8 ± 10.1 | 57.2 ± 10.1 |
| Sex: Female, Male(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Female | 81 | 76 | 81 | 238 |
| Male | 194 | 195 | 192 | 581 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 275 | 271 | 273 | 819 |
| Race (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 275 | 271 | 273 | 819 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Glycosylated Haemoglobin (HbA1c)(Percentage of HbA1c) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 8.52 ± 1.12 | 8.53 ± 1.05 | 8.32 ± 0.99 | 8.45 ± 1.06 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Ran from Nov 2015 to primary completion in Dec 2017, 24 months.
Results were first posted in Jul 2019, 1 year 7 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide